Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Leukemia
 More »

  • Pharma Touting Phase II/III Wins in Run-Up to ASCO
    Meantime, Roche's Genentech is reporting Phase III successes for its investigational drug GA101 for the treatment of chronic lymphocytic leukemia (CLL). Presenting results from its ...
    5-16-2013
  • Companion Diagnostics: 52 Pick-Up
    ... commercialize the test internationally. Leukemia, lymphoma, and myeloma specialists at ... methyltransferase for mixed lineage leukemia (MLL-r), a subtype of both acute myeloid ...
    5-9-2013
  • Foundation Medicine Taps Sloan-Kettering Clinical, Genomics Expertise...
    Through this collaboration, leukemia, lymphoma, and myeloma specialists at Sloan-Kettering will provide clinical and genomic expertise to assist in product development. The ...
    5-2-2013
  • Novartis, Oxford BioMedica Ink Production Agreement for Lentiviral...
    for Novartis' use as part of its CTL019 leukemia program, a collaboration with scientists ... including chronic lymphocytic leukemia, B-cell acute lymphocytic leukemia, and ...
    5-1-2013
  • Triple Threat: Gene Controls Three Diseases
    is characterized by progressive bone marrow failure, congenital malformations, and a predisposition to cancer-particularly a high risk of developing leukemia and mouth tumors. ...
    4-26-2013
  • "GEN 10" Award Winners Announced
    Arathi Jayaraman, Illinois Institute of Technology, Abstract: Eradication of T-cell leukemia with epigenetic drugs Sun Kim, Illinois Institute of Technology, Abstract: Commercial ...
    4-22-2013
  • Report: Orphan Drugs Cheaper to Bring to Market, Offer Better...
    First approved in 1997 for the orphan treatment of non-Hodgkin B-cell lymphoma, Rituxan is also approved for chronic lymphocytic leukemia and has nonorphan approval for rheumatoid ...
    4-22-2013
  • Biosimilars: 10 Drugs to Watch
    ... mouse-human monoclonal antibody, for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis 2012 sales: $7.190 billion (CHF 6.707 billion) (Roche) 5 ...
    4-22-2013
  • Pharmacyclics Achieves Another $50M Milestone
    ibrutinib (PCI-32765) as a monotherapy versus chlorambucil in patients 65 years or older with treatment-naïve chronic lymphocytic leukemia/small lymphocyctic lymphoma (CLL/SLL). ...
    4-11-2013
  • AACR Rally for Medical Research
    Brian Boucher, whose daughter was diagnosed with a unique type of acute lymphoblastic leukemia at 15-months old, took the podium and noted that if this had happened in 1962 his ...
    4-8-2013
  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    ... Pfizer Indication(s): Chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior therapy Date of FDA ...
    4-4-2013
  • Major Advance: Novel DNA Cancer-Associated Variants Identified
    ... in Spain that was published in Nature Genetics, which relates the role of telomeres and their protective function of DNA with the development of chronic lymphocytic leukemia. ...
    3-28-2013
  • Tracking White Blood Cell Counts at Home
    Portable leukocyte counters could improve outpatient monitoring of patients with chronic conditions such as leukemia or other cancers. The counters could be used in combination ...
    3-27-2013
  • Clinigen Buys Cardioxane from Novartis for $33M
    the anti-viral active against cytomegalovirus (CMV) acquired from AstraZeneca in March 2010 and commonly used to support leukemia patients undergoing bone marrow transplants. ...
    3-26-2013
  • Cell Therapy Leads to ALL Remission
    An experimental cell therapy that manipulates the immune system to treat the normally deadly recurrent B-cell acute lymphoblastic leukemia (ALL) showed success in Phase I of an ...
    3-21-2013
  • More »

    Journal Articles

  • Adipose-Tissue-Derived and Wharton's Jelly-Derived Mesenchymal...
    Mehdi Najar, Gordana Raicevic, Hicham Id Boufker, Hussein Fayyad-Kazan, Cécile De Bruyn, Nathalie Meuleman, Dominique Bron, Michel Toungouz, Laurence Lagneaux
    Tissue Engineering, Part A
    Lymphocyte Responses by Secreting Leukemia Inhibitory Factor Tissue Engineering, ... We also evaluated MSC expression of leukemia inhibitory factor and the role of this ...
  • Characterization of Danio rerio Nanog and Functional Comparison...
    Maximilian Schuff, Doreen Siegel, Melanie Philipp, Karin Bundschu, Nicole Heymann, Cornelia Donow, Walter Knöchel
    Stem Cells and Development
    Vice versa, zebrafish Nanog was found to promote proliferation and to inhibit differentiation of mouse embryonic stem cells in the absence of leukemia inhibitory factor. These ...
  • Generation of Neural Stem Cells from Embryonic Stem Cells Using...
    James W. Rowland, Jason J. Lee, Ryan P. Salewski, Eftekhar Eftekharpour, Derek van der Kooy, Michael G. Fehlings, Eftekkar Eftekharpour
    Stem Cells and Development
    The default mechanism can be used to derive clonal neurosphere-forming populations of neural stem cells that have been termed leukemia inhibitory factor-dependent primitive neural ...
  • Optimization of Protocols for Derivation of Mouse Embryonic Stem...
    Timothy J. Davies, Paul J. Fairchild
    Stem Cells and Development
    Here, we report the development of protocols for the derivation of novel ESC lines from C57Bl/6 mice based on the combined use of high concentrations of leukemia inhibitory factor ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll